Efficacy News and Research

RSS
Targacept plans to pursue development of TC-5214 for overactive bladder

Targacept plans to pursue development of TC-5214 for overactive bladder

DuraSite 2 ophthalmic drug delivery system from InSite Vision

DuraSite 2 ophthalmic drug delivery system from InSite Vision

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Janssen receives FDA Priority Review for bedaquiline NDA to treat MDR-TB

Janssen receives FDA Priority Review for bedaquiline NDA to treat MDR-TB

NeuroSigma's external Trigeminal Nerve Stimulation system awarded CE Certification

NeuroSigma's external Trigeminal Nerve Stimulation system awarded CE Certification

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

Epizyme commences EPZ-5676 Phase 1 study for MLL-r leukemia

Epizyme commences EPZ-5676 Phase 1 study for MLL-r leukemia

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Phase 1b trial validates efficacy of Pulmatrix PUR118 to treat COPD

Phase 1b trial validates efficacy of Pulmatrix PUR118 to treat COPD

Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B

Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B

FDA approves Bosulif to treat chronic myelogenous leukemia

FDA approves Bosulif to treat chronic myelogenous leukemia

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

EC grants European market authorization for Revestive to treat short bowel syndrome

EC grants European market authorization for Revestive to treat short bowel syndrome

Pediatric central line infections reduced by ‘best practice’ guidelines

Pediatric central line infections reduced by ‘best practice’ guidelines

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

Scientists discover new anti-cancer and anti-metastatic molecule

Scientists discover new anti-cancer and anti-metastatic molecule

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

Usefulness of liver biopsy for CALI preoperative assessment questioned

Usefulness of liver biopsy for CALI preoperative assessment questioned

New analyses from Esbriet RECAP study in IPF patients presented at ERS 2012

New analyses from Esbriet RECAP study in IPF patients presented at ERS 2012

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.